## 2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one: A Promising Candidate for Drug Development
This long chemical name describes a molecule with a complex structure, which belongs to the **quinazolinone** family. Quinazolinones are known for their diverse pharmacological activities, including:
* **Anti-cancer:** Some quinazolinones have shown potential in treating various cancers like breast, lung, and colon cancer.
* **Anti-inflammatory:** Their ability to inhibit inflammatory pathways makes them promising candidates for treating conditions like arthritis and inflammatory bowel disease.
* **Anti-bacterial:** Certain quinazolinones have shown activity against bacteria, suggesting their potential as antibacterial agents.
* **Anti-viral:** Some studies suggest that certain quinazolinones might be effective against viral infections.
* **Anti-diabetic:** Some quinazolinones exhibit insulin-sensitizing properties, making them a potential target for diabetes treatment.
**Why is 2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one specifically important for research?**
This particular molecule, while not yet widely studied, holds promise based on its structural features:
* **Multiple functional groups:** The molecule contains various functional groups like hydroxyl, methoxy, and aromatic rings, allowing for diverse interactions with biological targets.
* **Potential for modifications:** Its complex structure offers multiple sites for chemical modifications, allowing researchers to fine-tune its properties and enhance its biological activity.
* **Previous success:** Other quinazolinones with similar structural features have shown promising pharmacological activity, suggesting potential for this molecule.
**Research Significance:**
The molecule's potential as a drug candidate is a significant factor driving its research. Scientists are investigating its:
* **Biological activity:** Studies are underway to assess its effectiveness against various diseases, including cancer, inflammation, and bacterial infections.
* **Pharmacokinetic properties:** Researchers are evaluating how the body absorbs, distributes, metabolizes, and eliminates this molecule to understand its suitability for drug development.
* **Safety profile:** Extensive testing is required to determine its potential toxicity and side effects before it can be considered for human use.
**Overall, 2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one is a promising molecule that warrants further investigation due to its potential for developing new drugs with diverse therapeutic applications.**
**Note:** This information is based on general knowledge about quinazolinones and the structural features of the molecule. Further research is needed to fully understand its specific properties and potential applications.
ID Source | ID |
---|---|
PubMed CID | 644412 |
CHEMBL ID | 1560043 |
CHEBI ID | 114876 |
Synonym |
---|
BAS 06731041 |
smr000013888 |
2-(4-hydroxy-3-methoxy-phenyl)-3-(2-methoxy-phenyl)-2,3-dihydro-1h-quinazolin-4-one |
MLS000033806 |
OPREA1_392639 |
CHEBI:114876 |
AKOS000534357 |
2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-2,3-dihydroquinazolin-4(1h)-one |
STK831679 |
2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one |
MLS002538240 |
HMS2333G20 |
AKOS022144481 |
CHEMBL1560043 |
sr-01000363838 |
SR-01000363838-1 |
Q27196688 |
Class | Description |
---|---|
quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 32.4648 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 32.4648 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
ClpP | Bacillus subtilis | Potency | 31.6228 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 100.0000 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0018 | 15.6638 | 39.8107 | AID894 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 0.7943 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |